조항 목차
- PrinciplePrinciple
- 2.1The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. Senior management…
- 2.2The manufacturer must have an organisation chart in which the relationships between the heads of Production, Quality Control and where appl…
- 2.3People in responsible positions should have specific duties recorded in written job descriptions and adequate authority to carry out their…
- 2.4Senior management has the ultimate responsibility to ensure an effective quality management system is in place to achieve the quality objec…
- 2.5Senior Management should appoint Key Management Personnel including the head of Production, the head of Quality Control, and if at least on…
- 2.6The duties of the Qualified Person(s) are described in Article 51 of Directive 2001/83/EC, and can be summarised as follows: a) for medicin…
- 2.7The head of the Production Department generally has the following responsibilities: i. To ensure that products are produced and stored acco…
- 2.8The head of Quality Control generally has the following responsibilities: i. To approve or reject, as he sees fit, starting materials, pack…
- 2.9The heads of Production, Quality Control and where relevant, Head of Quality Assurance or Head of Quality Unit, generally have some shared,…
- 2.10The manufacturer should provide training for all the personnel whose duties take them into production and storage areas or into control lab…
- 2.11Besides the basic training on the theory and practice of the quality management system and Good Manufacturing Practice, newly recruited per…
- 2.12Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitising…
- 2.13Visitors or untrained personnel should, preferably, not be taken into the production and quality control areas. If this is unavoidable, the…
- 2.14The pharmaceutical quality system and all the measures capable of improving its understanding and implementation should be fully discussed…
- 2.15Detailed hygiene programmes should be established and adapted to the different needs within the factory. They should include procedures rel…
- 2.16All personnel should receive medical examination upon recruitment. It must be the manufacturer’s responsibility that there are instructions…
- 2.17Steps should be taken to ensure as far as is practicable that no person affected by an infectious disease or having open lesions on the exp…
- 2.18Every person entering the manufacturing areas should wear protective garments appropriate to the operations to be carried out.
- 2.19Eating, drinking, chewing or smoking, or the storage of food, drink, smoking materials or personal medication in the production and storage…
- 2.20Direct contact should be avoided between the operator’s hands and the exposed product as well as with any part of the equipment that comes…
- 2.21Personnel should be instructed to use the hand-washing facilities.
- 2.22Any specific requirements for the manufacture of special groups of products, for example sterile preparations, are covered in the annexes.
- 2.23Consultants should have adequate education, training, and experience, or any combination thereof, to advise on the subject for which they a…
표지·목차 원문
Ref. Ares(2014)968076 - 28/03/2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Public Health and Risk Assessment Medicinal Product – quality, safety and efficacy
Brussels, 16 August 2013
EudraLex
The Rules Governing Medicinal Products in the European Union
Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use
Part 1 Chapter 2: Personnel
Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.
Status of the document: Revisiona
Reasons for changes: Changes have been made in order to integrate the principles of “Pharmaceutical Quality System” as described in the ICH Q10 tripartite guideline. A section has been added on consultants
Deadline for coming into operation: 16 February 2014
Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11
a On 26 March 2014 minor change to references to in paragraph 2.5 to other paragraphs of Chapter 2.
출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15